Try Yahoo Finance on Firefox| Prev Close: | 73.78 |
|---|---|
| Open: | 73.75 |
| Bid: | 72.62 x 100 |
| Ask: | 74.98 x 100 |
| 1y Target Est: | 76.48 |
| Beta: | 0.886856 |
| Next Earnings Date: | 28-Jul-16 |
| Day's Range: | 73.29 - 74.19 |
|---|---|
| 52wk Range: | 51.82 - 75.12 |
| Volume: | 4,255,906 |
| Avg Vol (3m): | 5,910,500 |
| Market Cap: | 123.16B |
| P/E (ttm): | 79.25 |
| EPS (ttm): | 0.93 |
| Div & Yield: | 1.52 (2.06%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- [$$] Business Watchat The Wall Street Journal(Wed 1:04AM EDT)
- Bristol-Myers Brings Back One That Got Awayat Bloomberg(Tue, Jul 5)
- UK cost agency rejects Bristol's Opdivo for kidney cancerReuters(Tue, Jul 5)
- Bristol-Myers (BMY) Stock Slides on Swedish Acquisitionat TheStreet(Tue, Jul 5)
- Bristol-Myers buys Swedish company with immunotherapy treatmentat MarketWatch(Tue, Jul 5)
- [$$] Bristol-Myers Buys Swedish Firm With Immunotherapy Treatmentat The Wall Street Journal(Tue, Jul 5)
- Bristol-Myers Squibb Buys Privately Held Cormorant PharmaceuticalsBenzinga(Tue, Jul 5)
- 7:00 am Bristol-Myers acquires Cormorant Pharmaceuticals for an upfront payment of $95 mln & additional consideration of $425 mln upon the achievement of certain regulatory milestones/developmentsBriefing.com(Tue, Jul 5)
- Bristol-Myers Squibb Acquires Cormorant PharmaceuticalsBusiness Wire(Tue, Jul 5)
- Major Change AfootYahoo Finance Contributors(Mon, Jul 4)
- The Big Loser After Gilead's Latest Approval May Not Be Who You Think (Hint: It's not AbbVie, Inc.)at Motley Fool(Sun, Jul 3)
- Hunting for valueCNBC(Fri, Jul 1)
- 5 Low Beta Stocks to Withstand Market VolatilityZacks(Fri, Jul 1)
- Bristol-Myers, PsiOxus Strike Immuno-Oncology CollaborationZacks(Fri, Jul 1)
- Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and EnadenotucirevBusiness Wire(Thu, Jun 30)
Press Releases
- Bristol-Myers Squibb Acquires Cormorant PharmaceuticalsBusiness Wire(Tue, Jul 5)
- Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and EnadenotucirevBusiness Wire(Thu, Jun 30)
- Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder CancerBusiness Wire(Mon, Jun 27)
